PROCEPT BioRobotics Corporation Common Stock (PRCT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.04 (-0.04%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of PROCEPT BioRobotics Corporation Common Stock (PRCT)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Key Insights

Critical company metrics and information
  • Share Price

    $92.78
  • Market Cap

    $5.02 Billion
  • Total Outstanding Shares

    54.11 Million Shares
  • Total Employees

    626
  • Dividend

    No dividend
  • IPO Date

    September 15, 2021
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.procept-biorobotics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$172.87 Million
Net Cash Flow From Investing Activities$-17.48 Million
Net Cash Flow From Operating Activities, Continuing$-91.76 Million
Net Cash Flow, Continuing$63.63 Million
Net Cash Flow From Operating Activities$-91.76 Million
Net Cash Flow From Investing Activities, Continuing$-17.48 Million
Net Cash Flow$63.63 Million
Net Cash Flow From Financing Activities$172.87 Million

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$-103.71 Million
Operating Expenses$206.29 Million
Diluted Average Shares$100.75 Million
Research and Development$56.68 Million
Cost Of Revenue$79.93 Million
Net Income/Loss Available To Common Stockholders, Basic$-103.71 Million
Preferred Stock Dividends And Other Adjustments$0.00
Benefits Costs and Expenses$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-103.71 Million
Gross Profit$96.64 Million
Basic Average Shares$100.75 Million
Income/Loss From Continuing Operations Before Tax$176.57 Million
Revenues$176.57 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Earnings Per Share$-2.06
Costs And Expenses$286.22 Million
Diluted Earnings Per Share$-2.06
Operating Income/Loss$-109.64 Million
Net Income/Loss$-103.71 Million
Selling, General, and Administrative Expenses$149.61 Million

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Noncurrent Assets$52.46 Million
Other Current Assets$278.03 Million
Current Assets$321.89 Million
Noncurrent Liabilities$79.73 Million
Other Non-current Liabilities$28.32 Million
Assets$374.35 Million
Equity Attributable To Parent$251.78 Million
Equity$251.78 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$32.90 Million
Liabilities And Equity$374.35 Million
Fixed Assets$27.68 Million
Accounts Payable$9.95 Million
Long-term Debt$51.40 Million
Current Liabilities$42.84 Million
Inventory$43.87 Million
Other Non-current Assets$24.78 Million
Liabilities$122.57 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.